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The novelty and impact of the work: This study based on nationwide registers provides 
evidence that family history of cancer is a prognostic factor for cancers at some sites and histological 
type of cancer also has further prognostic value. Patients with familial breast and prostate cancer have 
better survival. The poor survival for patients with familial ovarian cancer is multifactorial. 
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Abstract 
Family history of cancer is a well-known risk factor but the role of family history in survival is less 
clear. The aim of this study was to investigate the association between family history and cancer 
survival for the common cancers in Sweden. 
Using the Swedish population-based registers, patients diagnosed with the most common cancers 
were followed for cancer-specific death during 1991-2010. We used multivariate proportional hazards 
(Cox) regression models to contrast the survival of patients with a family history of cancer 
(individuals whose parent or sibling had a concordant cancer) to the survival of patients without a 
family history.  
Family history of cancer had a modest protective effect on survival for breast cancer (hazard ratio 
(HR) = 0.88, 95% confidence interval (95% CI) = 0.81 to 0.96) and prostate cancer (HR = 0.82, 95% 
CI = 0.75 to 0.90). In contrast, family history of cancer was associated with worse survival for 
nervous system cancers (HR = 1.24, 95% CI = 1.05 to 1.47) and ovarian cancer (HR = 1.20, 95% CI = 
1.01 to 1.43). Furthermore, the poorer survival for ovarian cancer was consistent with a higher FIGO 
stage and a greater proportion of more aggressive tumors of the serous type. 
The better survival for patients with a family history of breast and prostate cancer may be due to 
medical surveillance of family members. The poor survival for ovarian cancer patients with an 
affected mother or sister is multifactorial, suggesting that these cancers are more aggressive than their 
sporadic counterparts. 
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Introduction 
	
Family history of cancer is considered an important risk factor and extensive work has 
been done to understand the risk associated with a family history for different cancers.1-4 In addition 
to the risk of developing cancer, family history of cancer survival has been suggested to be important 
for the cancer survival of a newly diagnosed individual.5 
We have previously shown that survival from cancer is in part inherited.6, 7 One 
potential explanation for the association of survival among family members could be that relatives are 
at higher risk to develop a cancer tumor of predefined biology. Indeed, it has been shown that carriers 
of mutations in high-risk genes are more likely to develop a specific subtype of cancer.8 It is also 
possible that the survival concordance in families is related to the inheritance of host characteristics 
for instance affecting the ability to mount an effective anti-tumoral immune response or respond to 
cancer therapy.9 Furthermore, shared characteristics such as health-seeking behavior, treatment 
choices and life-style, are likely to be important for explaining the survival similarities among 
relatives.10 Although we and others have investigated the concordance of survival in families, much 
less is known about differences in survival for patients with a family history of cancer as compared to 
patients without a family history (sporadic cancer).11, 12  
Therefore our aim in this study was to determine whether patients with a family history 
of cancer have a differential survival as compared to patients without a family history of cancer. 
Using Swedish population-based registers, we studied familial cancers with sufficient sample sizes to 
consider the kinship of affected relatives. For those cancers with any significant association, we 
explored in depth the effect of age at diagnosis and the histological tumor type on survival differences, 
and examined the association between stage information at diagnosis and family history of cancer.  
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Materials and Methods 
 
Data Sources 
The data for this study is from a linkage of several Swedish population- based registers 
that has been described previously.4 Individuals included in this study are all recorded in the Swedish 
Cancer Register with a first primary malignancy from January 1, 1991 to December 31, 2009. To 
obtain the exposure information (i.e. family history of cancer), these patients are linked to their first 
degree relatives in the Swedish Multi-Generation Register. The Swedish Multi-Generation Register 
records the biological parents for all children born in Sweden from 1932 who were alive in 1961, with 
essentially complete parental information from 1991.13 The cancer diagnoses of these family members 
were obtained from the Swedish Cancer Register (which was established in 1958 14). We selected two 
cohorts of children for analysis: The first cohort included individuals with both biological parents 
identified (to investigate the effect of parental cancer history on survival), and the second cohort 
included individuals with at least one sibling (to investigate sibling effects). We followed these 
individuals for cancer-specific death in the Cause of Death Register which was available up to the end 
of 2010 with a reported accuracy of 96%.6 Some additional information for censoring (date of 
emigration) was obtained from the Total Population Register and socioeconomic status was obtained 
from the census files from 1960, 1970, 1980, 1990. 
Cancers Studied 
The Swedish Cancer Register records all malignant cancers diagnosed since 1958 
according to the seventh revision of the International Classification of Disease (ICD7). We included 
cancers that provided a sufficient sample size to address our hypotheses, namely stomach (ICD7=151), 
colorectal (ICD7=153-4), lung (ICD7=162-3), breast (ICD7=170), ovarian (ICD7=175), prostate 
(ICD7=177), kidney (ICD7=180), bladder (ICD7=181), melanoma (ICD7=190), nervous system 
(ICD7=193), non-Hodgkin’s lymphoma (ICD7=200, 202) and leukemia (ICD7=204-209). 15 For 
cancer of the nervous system and leukemia, we only included patients who were at least 15 years old 
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at primary tumor diagnosis because types of childhood cancers are often different from the types of 
adult cancers.16, 17 
Variables 
In addition to the ICD codes, the Swedish Cancer Register records information on 
histopathological type and patho-anatomic diagnosis	(PAD), according to WHO/HS/CANC/24.1. The 
information on histological type enables cancers to be classified into main subgroups, such as 
adenocarcinoma and squamous cell carcinoma.1 Detailed morphologic information, the Systematized 
Nomenclature of Human Medicine histology (SNOMED, http://snomed.org), was available from 1993 
according to ICD-O/2 (2nd Edition. WHO Geneva 1990) and from 2005 according to ICD-O/3 (3rd 
Edition WHO Geneva 2000).18 Stage information was collected since 2004 according to FIGO (The 
International Federation of Gynecology and Obstetrics, http://www.figo.org) for gynecological tumors 
or TNM stage (tumor size (T), lymph nodal involvement (N) and metastatic (M) status) for other 
tumors 19 except those of the nervous-system, lymphomas and leukemia.18, 20 The completeness of 
cancer registration (with cytological or histological verification) is considered high.18  
Our outcome variable, cancer-specific death, was defined by the underlying cause of 
death in the Swedish Cause of Death Register which is recorded using ICD codes. Our main exposure, 
family history of cancer, was defined as having at least one parent or sibling with a record of a 
diagnosis of a concordant cancer. The region in which the cancer diagnosis was registered, which was 
available from the Swedish Cancer Register, was classified as six medical regions.18 The 
socioeconomic status from the Census data was grouped into five categories; blue-collar workers, 
white collar workers, self-employed workers, farmers and unclassified.   
Statistical Methods 
Our main analyses compared the cancer-specific survival for up to 5-years after 
diagnosis for patients with and without a family history of cancer. Using multivariate proportional 
hazards (Cox) regression models, we estimated the hazard ratio (HR) of cancer-specific death for 
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patients with a family history of the specific cancer as compared to patients without a family history 
(the reference group). In these analyses we adjusted for gender, age and calendar year of diagnosis, 
socioeconomic status and the region where the individual was diagnosed with cancer. Survival time 
was defined as the elapsed time from the date of cancer diagnosis until the date of cancer-specific 
death or censoring (death due to other causes, emigration, end of study, or 31 December 2010, 
whichever occurred first) within 5 years of diagnosis. If there was no other censoring event, patients 
were censored at 5 years after diagnosis. We also conducted stratified analyses by type of relationship 
(affected parent or sibling), age at diagnosis (classified as above or below the median) and by the 
specific histological type of cancer (subtype for leukemia).  
Since any difference in survival between patients with a family history and patients 
without a family history might be due to differences in histology distribution or differential survival 
within histological type, we compared the distribution of the histological type in the familial and 
sporadic cases (for the period from 1993 when SNOMED codes became available) and estimated the 
mortality in the five years following diagnosis for each histological type. Leukemia subtypes defined 
using the fourth digit of the ICD7 code3 were analyzed for the same period. The distribution of tumor 
histological type in patients with or without a family history was compared using the Pearson Chi-
square test. For cancers with significant results from the Pearson Chi-square test, post-hoc tests 
contrasting each histological type against the others were conducted and Bonferroni corrections used 
for p-value adjustment.  
In addition, we investigated whether there is a differential survival for patients with a 
family history compared to patients without a family history of cancer associated with stage (TNM 
stage at cancer diagnosis for stomach, breast and prostate cancers, or with FIGO stage for ovarian 
cancer). For this analysis, we performed a logistic regression with stage information as outcome, 
family cancer history as the main exposure, and adjusting for sex, age at diagnosis, year of diagnosis, 
socioeconomic status and region. We present odds ratios (ORs) that provide a measure of the 
frequency of combined higher categories of stage relative to the lowest category in patients with a 
family history compared with patients without a family history of concordant cancer (i.e., T2-T4 vs 
T1). Where there were any significant differences, we investigated each of the higher categories 
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separately. These analyses were conducted for the period from 2004 when stage information was 
available.  
All data preparation and analyses were performed using the SAS statistical package, 
version 9.4 (SAS Institute, Cary NC).21 
 
Results 
The study population for each cancer investigated is described in Table 1, including the 
total number of patients diagnosed with the cancer, number of cancer-specific deaths and median age 
at diagnosis.  
In Table 2, we present the hazard ratios of cancer-specific death within five years for 
cancer patients with a family history compared to cancer patients without a family history. For breast 
cancer, prostate cancer and leukemia, we found that a concordant family cancer history played a 
protective role for cancer survival in patients: hazard ratio (HR) was 0.88, (95% confidence interval 
(CI) = 0.81 to 0.96) for breast cancer, HR = 0.82, (95% CI = 0.75 to 0.90) for prostate cancer, and HR 
= 0.70, (95% CI = 0.54 to 0.92) for leukemia. In contrast, familial cancer patients had worse survival 
for patients with ovarian cancer and nervous system cancer: HR = 1.20, (95% CI = 1.01 to 1.43) and 
HR = 1.24, (95% CI = 1.05 to 1.47), respectively.  
For the six cancers that had any significant association, in Table 2, we further 
investigated the role of age, kinship, and histological type in the differential cancer survival. For 
breast and prostate cancer and leukemia, the protective effect was strongest in younger patients (Table 
3, last column). Familial ovarian cancer patients who were diagnosed at younger ages had consistently 
significantly higher risk of death in the 5 years after the cancer diagnosis than patients with sporadic 
cancer, HR = 1.44, (95% CI = 1.14 to 1.81) and the relative risk was highest when a sister was 
affected, HR = 1.75, (95% CI = 1.23 to 2.49).  
Comparing the distribution of the histological type between familial and sporadic 
cancers, we found significant differences for breast cancer, ovarian cancer and leukemia (Table 4, last 
8	
	
five columns).  Lobular breast cancer, which has a lower mortality rate than the more common ductal 
type, was slightly more common in breast cancer patients with a family history than in patients 
without a family history, 14.1% versus 12.8% (p = 0.015).  Serous ovarian cancer was more often 
detected in familial cancer patients (54.8% for familial cancer patients vs. 43.3% for sporadic cancer 
patients) (p = 0.001) and the very high mortality rate for serous ovarian cancer thus contributes to the 
higher risk of cancer death in familial ovarian cancer patients. Lymphatic leukemia was more 
common among familial cases of adult leukemia (p < 0.001) and the lower mortality rate for this 
subtype thus explains in part the protective effect of family history.  
 The associations between family cancer history and survival for each specific 
histological type of cancer are presented in Table 5. For ductal breast cancer and adenocarcinoma of 
the stomach and prostate, patients with a family history had better survival than patients without a 
family history with the same histological type (HR ranging from 0.80 to 0.86). However, for 
mucinous ovarian cancer, patients whose mother or sister was diagnosed with the same cancer had 
twice the risk of death compared to sporadic cancer patients, HR = 2.09, (95% CI = 1.09 to 3.98).  For 
nervous system cancer, patients with a family history had much worse survival than patients without a 
family history when their cancer was gliomas of uncertain origin, HR = 2.78, (95% CI = 1.16 to 6.65) 
or classified as ‘other’ histological type, HR = 2.35, (95% CI = 1.12 to 4.93).  
  Finally, we explored the stage information at diagnosis in patients with a family history 
and patients without a family history of concordant cancer (Table 6). Prostate cancer patients with a 
family history were less likely to be diagnosed with tumors of larger size/extent compared to patients 
without a family history (p=0.006). Family cancer history of prostate cancer was associated with a 
reduction of 11% in the odds of tumors diagnosed in the T3 category (OR = 0.89, 95% CI = 0.81 to 
0.97, T3 vs T1), consistent with the protective effect we observed for family history. We observed a 
large and significant increase in the odds of higher FIGO stages vs the lowest stage (stage I) for 
ovarian cancer OR = 2.70, (95% CI = 1.46 to 4.97) and a significant OR for each of stages II, III and 
IV: OR = 2.79, (95% CI = 1.21 to 6.40) for stage II, OR = 2.52, (95% CI = 1.33 to 4.79) for stage III, 
and OR = 3.22, (95% CI = 1.52 to 6.79) for stage IV, respectively.  
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Although there was no significant difference in TNM stage in breast cancer patients 
with and without a family history of breast cancer, we implemented additional analysis for the two 
main histological types (ductal and lobular) which had sufficient number of cases (Supplementary 
Table 1). For ductal breast cancer, patients with family history of breast cancer tended to be diagnosed 
with smaller tumor size (p=0.01) with an OR of 0.88, (95% CI = 0.78 to 0.98) for T2-T4 vs T1. For 
lobular breast cancer, a family cancer history of breast cancer was associated with an increase in the 
odds of positive nodal involvement vs. negative nodal involvement: OR=1.33, (95% CI = 1.02 to 
1.73).  
 
Discussion 
We have demonstrated a different role for family history of cancer in cancer survival 
for 5 years after diagnosis depending on the cancer site; a protective effect for stomach cancer, breast 
cancer, prostate cancer and leukemia but a poorer survival for ovarian cancer and nervous system 
cancers. No associations were found for lung cancer, kidney cancer, bladder cancer, melanoma or 
non-Hodgkin’s lymphoma. The potential explanations for the differential survival varied with cancer 
site: earlier stage at diagnosis for familial prostate cancer, a higher proportion of a less aggressive 
subtype for familial leukemia and differential survival within histological type of nervous system 
cancers. For ovarian cancer, the much poorer survival for familial cancers had a contribution from all 
of these factors, reflecting highly aggressive tumors in familial cases and suggesting that these may 
have a distinct genetic profile that has not yet been characterized.  
Since each cancer has a different prognosis, we chose to focus on the 5-year interval 
following diagnosis, as this is common in cancer recurrence and survivorship studies.22 However, 
breast cancer and prostate cancer have much lower mortality than the other cancers studied (Table 4) 
so that a longer period of follow-up would be more appropriate. We repeated our comparison of 
familial and non-familial breast and prostate cancer using all available follow-up time and none of 
these analyses changed our current conclusions. (Supplementary Table 2) In sensitivity analyses, we 
compared cancer-specific overall survival after diagnosis for familial cancer patients to the cancer-
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specific overall survival of sporadic cancer patients and also implemented our analyses on a wider 
cohort of cancer patients diagnosed during 1961-2009, and these analyses did not change our current 
conclusion (data not shown). 
For most common cancers, few systematic and detailed investigations of survival 
differences between familial and sporadic cancer have been done previously, but our findings are 
consistent with earlier studies on familial survival for stomach cancer, ovarian cancer and bladder 
cancer.11, 12, 23, 24 Recently, Kharazmi et al. (2016) compared survival in familial and non-familial 
breast cancer by age and stage at diagnosis using the Swedish Family-Cancer Database. 25 They found 
no evidence for familial breast cancer diagnosis at an earlier TNM stage compared to sporadic cases, 
which is in line with our findings in Table 6. However, we did find evidence that for ductal breast 
cancer, familial cases are diagnosed with smaller tumor size, consistent with the survival advantage 
we observed. In addition, our histology-specific mortality rates were largely in agreement with the 
literature on cancer survival, with poorer survival for ductal breast cancer,26, 27 signet ring stomach 
cancer,28 non-adenocarcinoma prostate cancer,29 serous ovarian cancer,11 astrocytic nervous system 
cancers and gliomas of uncertain origin,30 and a significantly better survival for lymphatic leukemia 
than for other subtypes.31   
A small survival benefit was seen in patients with a family history of breast cancer in 
our study, which was more pronounced if the affected relative was a sister. Thus, even with 
nationwide mammographic screening since the 1990s in Sweden,32 this finding suggests earlier 
detection due to increased awareness and positive medical surveillance in women with a family 
history of breast cancer. Such lead time bias was apparent for ductal breast cancer, the most common 
histological type, where we found that patients with a family history were more often diagnosed with 
smaller tumors. In contrast, for lobular breast cancer, which accounted for approximately 13% of all 
breast cancers and is harder to detect by mammography,27 familial cases tended to have larger tumor 
sizes and cases were at increased risk to be diagnosed with lymph node positive tumors. While this 
suggests a more aggressive disease in familial lobular breast cancer, there was no evidence of a higher 
cancer-specific mortality in familial cases. A possible interpretation is that familial lobular cancer is 
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somehow different than sporadic and that more research of this specific histological type is needed, in 
particular since it is known to be hard to detect through mammographic screening.  
Even though some early studies suggested that familial disease may have a more 
aggressive course in prostate cancer, the overall data suggest that the survival of patients with a family 
history is not essentially different from that of patients without a family history of prostate cancer.33-35 
Prostate-specific antigen (PSA) testing has been suggested to be one of the reasons for the 
inconsistent results.33 PSA testing was introduced in Sweden in the mid-1990s with a rise in incidence 
reported after this time.36 In a previous study, we reported a significantly increased risk of prostate 
cancer diagnosis shortly after a diagnosis in a brother in the calendar period after the introduction of 
PSA testing.4 Since prostate cancer has a long lead time37, this suggests that sons or brothers of 
prostate cancer patients may be more likely to seek medical attention and thus have higher probability 
of early detection due to the opportunistic screening, which in turn will contribute to a protective 
effect of family history such as we observed. We also found a significantly reduced risk of familial 
prostate cancer patients being diagnosed with a larger tumor, again reflecting lead-time bias in these 
patients.  
The protective effect of family history for leukemia is consistent with the 
preponderance of lymphatic leukemia, which is well known to be more familial than other subtypes,38-
40 and the better survival of this subtype. 
Our findings of a poor survival in women with a family history of ovarian cancer are in 
agreement with previous studies.11, 23 We found familial ovarian cancer patients who were diagnosed 
before 55 years of age had consistently significantly higher risk of death in the 5 years after the cancer 
diagnosis compared to patients with sporadic cancer. This might be due to germline mutations 
relevant to ovarian cancer.41 A contributing factor to the differences in survival for familial and 
sporadic cases of ovarian cancer is the distribution of histological types. In agreement with previous 
studies,42 we found serous ovarian cancer to be more familial than other histological types and 
BRCA1 or BRCA2 carriers are more likely to have this histology.43, 44 Since the survival is poorer for 
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serous histology than for other subtypes,11 this results in a higher risk of cancer death for familial 
cancers. However, for patients with serous ovarian cancer we found no evidence that family cancer 
history had any further effect on survival, in agreement with previous reports indicating that women 
with BRCA1/BRCA2 mutations can even have a survival advantage.43, 44 On the contrary, patients 
with familial mucinous ovarian cancer, who are not BRCA1 or BRCA2 mutation carriers,44  have 
increased risk of death in our data, possibly suggesting germline mutations associated with prognosis 
or therapy response. Since a reasonable proportion of ovarian cancers are mucinous, the differential 
survival for this histology type adds further to the risk of death associated with family history. We 
also observed that ovarian cancer patients with a family history were more likely to be diagnosed with 
tumor of higher FIGO stage than patients without a family history. In the absence of any available 
diagnostic test to date with sufficient accuracy to identify early-stage ovarian cancer,45 this is again 
consistent with more aggressive tumors in familial cases. 
For nervous system cancers, we found astrocytic histology to have the worst mortality 
rates, followed by gliomas of uncertain origin, findings that are in agreement with other studies.30 
Although the distribution of histological types was similar among patients with a family history and 
patients without a family history, the familial cancer patients with gliomas of uncertain origin had 
poorer survival than sporadic cancer patients.  
Strengths of this study include the use of Swedish population-based registers that have 
almost complete ascertainment of cancer cases providing an unbiased assessment of family history 
and long follow-up. The Swedish national cancer register has been validated and shown to have a high 
level of completeness (98%).18 In addition, the availability of information on detailed histological type 
and stage enables us to explore these factors in an effort to elucidate any noted differences in survival 
for familial and sporadic cancer patients.  
Despite the positive aspects of our study, the study also has several limitations. First, 
the Swedish Cancer Register contains no information on treatment, which might affect survival. 
However, it is unlikely that differential treatments are provided to familial and non-familial cancer 
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patients in Sweden, where the public health system provides similar treatment to all patients according 
to general guidelines.25 Nonetheless, regional differences in treatment might exist. Therefore, we 
adjusted all our models for the region where the patient was diagnosed. Changes in diagnosis and 
treatment protocols over time might also affect survival, and in an effort to adjust for these changes 
we also adjusted our models for calendar year of cancer diagnosis. Another limitation of our study is 
that there is no information on important risk factors such as obesity, alcohol consumption, and 
smoking.  
In conclusion, our findings provide evidence that family history of cancer is a 
prognostic factor for cancers at some sites and histological type of cancer also has further prognostic 
value. Further work is needed to understand the role of screening in family members. The strong 
association of more aggressive ovarian cancers in sisters and daughters of patients diagnosed with 
ovarian cancer may be informative for genetic counseling and help to guide further molecular or 
genetic investigations. 
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Table 1. Characteristics of cancer patients diagnosed between 1991 and 2009. 
Cancer	sites	 ICD7	
Parents	were	identifiable	 	 At	least	two	siblings	in	a	family	
n.	patients	 n.	deathsa	 Median	age	at	diagnosis	 	 n.	patients	 n.	deaths
a	 Median	age	at	diagnosis	
Stomach			 151	 3	788	 2	334	 59	 	 2	993	 1	826	 58	
Colorectal		 153-4	 23	928	 7	538	 60	 	 18	329	 5	699	 59	
Lung		 162-3	 16	972	 12	394	 60	 	 13	114	 9	521	 60	
Breastb		 170	 51	273	 4	372	 54	 	 40	738	 3	463	 54	
Ovarianb		 175	 6	377	 2	425	 55	 	 5	008	 1	882	 54	
Prostateb	 177	 41	383	 3	028	 63	 	 31	709	 2	264	 63	
Kidney		 180	 5	975	 1	836	 58	 	 4	636	 1	437	 58	
Bladder		 181	 9	021	 1	249	 60	 	 6	881	 921	 60	
Melanoma		 190	 16	929	 1	219	 51	 	 13	562	 959	 50	
Nervous	systemc		 193	 11	737	 3	731	 49	 	 9	565	 2	996	 50	
Non-Hodgkin’s	
lymphoma		 200,202	 9	025	 1	869	 56	 	 7	088	 1	453	 55	
Leukemiac		 204-9	 6	959	 1	763	 57	 	 5	469	 1	369	 56	
 
a Cancer-specific death within 5 years of cancer diagnosis 
b Sex-specific cancers 
c Excluded childhood cancers (diagnosis at age 0-14 years) 
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Table 2. Hazard ratios of cancer-specific death for familial cancer patients compared to sporadic cancer patients within 5 years of cancer diagnosis. 
Cancer	sites	
Parents	affected	 Siblings	affected	 familial	
n.	patients	 n.	death	 HR	&	95%	C.I.a	 n.	patients	 n.	death	 HR	&	95%	C.I.	a	 n.	patients	 n.	death	 HR	&	95%	C.I.	a	
Stomach	 195	 119	 0.82	(0.68-0.99)	 45	 31	 1.06	(0.74-1.51)	 236	 147	 0.85	(0.72-1.01)	
Colorectal	 2	563	 778	 0.94	(0.87-1.01)	 861	 272	 0.95	(0.84-1.07)	 3	274	 1000	 0.93	(0.87-1.00)	
Lung	 1	156	 860	 0.99	(0.93-1.07)	 625	 481	 1.04	(0.95-1.14)	 1	745	 1314	 1.01	(0.96-1.07)	
Breastb	 4	974	 403	 0.93	(0.83-1.03)	 3	062	 223	 0.81	(0.71-0.93)	 7	681	 599	 0.88	(0.81-0.96)	
Ovarianb	 204	 82	 1.09	(0.88-1.36)	 111	 58	 	 1.44	(1.11-1.88)	 305	 134	 1.20	(1.01-1.43)	
Prostateb	 6	427	 392	 0.81	(0.73-0.90)	 3	897	 260	 0.83	(0.73-0.95)	 9	494	 604	 0.82	(0.75-0.90)	
Kidney	 170	 53	 0.87	(0.66-1.15)	 71	 24	 0.88	(0.58-1.33)	 233	 75	 0.89	(0.70-1.12)	
Bladder	 417	 46	 0.79	(0.59-1.07)	 129	 16	 0.84	(0.51-1.39)	 535	 62	 0.81	(0.63-1.05)	
Melanoma	 583	 28	 0.72	(0.49-1.04)	 402	 34	 1.06	(0.75-1.50)	 947	 60	 0.88	(0.68-1.14)	
Nervous	systemc	 251	 93	 1.26	(1.02-1.55)	 154	 53	 1.22	(0.93-1.60)	 392	 142	 1.24	(1.05-1.47)	
Non-Hodgkin’s	
lymphoma	 205	 42	 0.94	(0.69-1.28)	 88	 25	 1.23	(0.83-1.83)	 291	 66	 1.02	(0.80-1.31)	
Leukemiac	 206	 40	 0.71	(0.52-0.98)	 84	 17	 0.69	(0.43-1.11)	 286	 56	 0.70	(0.54-0.92)	
 
a Hazard ratio (HR) with 95% confidence interval (C.I.) from Cox regression model adjusting for sex, age at diagnosis, year of diagnosis, socioeconomic status and region of cancer diagnosis. 
b Sex-specific cancers 
c Excluded childhood cancers (diagnosis at age 0-14 years) 
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Table 3. Hazard ratios of cancer-specific death for familial cancer patients compared to sporadic cancer patients within 5 years of cancer diagnosis, stratified 
by affected relative and by age. 
Cancer	sites	
Parents	affected	 Siblings	affected	 familial	
n.	patients	 n.	death	 HR	&	95%	C.I.a	 n.	patients	 n.	death	 HR	&	95%	C.I.	a	 n.	patients	 n.	death	 HR	&	95%	C.I.	a	
Stomach	 	 	 	 	 	 	 	 	 	
<	median	age	at	dx	 89	 53	 0.97	(0.73-1.28)	 19	 13	 0.87	(0.50-1.51)	 110	 68	 0.97	(0.76-1.24)	
≥	median	age	at	dx	 106	 66	 0.73	(0.57-0.94)	 26	 18	 1.22	(0.76-1.95)	 126	 79	 0.77	(0.61-0.98)	
Breastb	 	 	 	 	 	 	 	 	 	
<	median	age	at	dx	 2	638	 250	 0.94	(0.82-1.07)	 1	250	 105	 0.78	(0.64-0.95)	 3	710	 336	 0.87	(0.77-0.98)	
≥	median	age	at	dx	 2	336	 153	 0.90	(0.76-1.06)	 1	812	 118	 0.85	(0.71-1.03)	 3	971	 263	 0.89	(0.78-1.01)	
Ovarianb	 	 	 	 	 	 	 	 	 	
<	median	age	at	dx	 118	 48	 1.29	(0.97-1.73)	 61	 33	 1.75	(1.23-2.49)	 178	 80	 1.44	(1.14-1.81)	
≥	median	age	at	dx	 86	 34	 0.90	(0.64-1.27)	 50	 25	 1.17	(0.79-1.74)	 127	 54	 0.97	(0.74-1.28)	
Prostateb	 	 	 	 	 	 	 	 	 	
<	median	age	at	dx	 3	552	 228	 0.80	(0.70-0.92)	 1	815	 131	 0.79	(0.65-0.94)	 4	883	 327	 0.79	(0.70-0.90)	
≥	median	age	at	dx	 2	875	 164	 0.84	(0.71-0.98)	 2	082	 129	 0.88	(0.74-1.06)	 4	611	 277	 0.86	(0.76-0.98)	
Nervous	systemc	 	 	 	 	 	 	 	 	 	
<	median	age	at	dx	 131	 36	 1.53	(1.10-2.14)	 60	 11	 0.79	(0.43-1.43)	 180	 49	 1.32	(0.99-1.75)	
≥	median	age	at	dx	 135	 59	 1.13	(0.87-1.47)	 94	 42	 1.42	(1.05-1.93)	 212	 93	 1.20	(0.97-1.48)	
Leukemiac	 	 	 	 	 	 	 	 	 	
<	median	age	at	dx	 93	 15	 0.54	(0.32-0.92)	 25	 6	 0.88	(0.39-1.99)	 120	 21	 0.58	(0.37-0.91)	
≥	median	age	at	dx	 113	 25	 0.85	(0.57-1.28)	 59	 11	 0.62	(0.34-1.13)	 166	 35	 0.79	(0.56-1.11)	
 
a Hazard ratio (HR) with 95% confidence interval (C.I.) from Cox regression model adjusting for sex, age at diagnosis, year of diagnosis, socioeconomic status and region of cancer diagnosis. 
b Sex-specific cancers 
c Excluded childhood cancers (diagnosis at age 0-14 years) 
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Table 4. Overall 5-year mortality rate and distribution of histology by family cancer history among 
patients diagnosed with cancer between 1993 and 2009. 
 
Cancer	
sites	 histology	
n.patients	 n.deaths	
5-year	mortality	rate	
per	1000	person-
years	
n.patients	
sporadic	 (%)	 familial	 (%)	 P	a	
Stomach	 all	 3459	 2188	 367.9	(352.8-383.6)	 	 	 	 	 	
	 Adenocarcinoma	 2613	 1705	 415.2	(395.9-435.4)	 2434		 (75.3)	 179	 (79.6)	 	
	 Signet-ring	cell	
carcinoma	
441	 342	 497.3	(447.3-552.9)	
412	 (12.7)	 29	 (12.9)	 	
	 Others	 405	 141	 122.3	(103.7-144.3)	 388	 (12.0)	 17	 (7.6)	 0.13	
Breastb	 all	 47945	 3951	 19.8	(19.2-20.4)	 	 	 	 	 	
	 Tubular	 2557	 41	 3.5	(2.6-4.7)	 2157	 (5.3)	 400	 (5.6)	 	
	 Ductal	 32510	 2609	 19.5	(18.7-20.2)	 27723	 (67.9)	 4787	 (67.3)	 	
	 Lobular	 6240	 389	 14.7	(13.3-16.2)	 5240	 (12.8)	 1000	 (14.1)	 *	
	 Others	 6638	 912	 24.2	(22.7-25.8)	 5708	 (14.0)	 930	 (13.1)	 0.01 
Ovarianb	 all	 5884	 2233	 114.8	(110.1-119.7)	 	 	 	 	 	
	 Serous	 2579	 1167	 144.3	(136.2-152.8)	 2425	 (43.3)	 154	 (54.8)	 *	
	 Mucinous	 539	 158	 85.7	(73.3-100.2)	 523	 (9.3)	 16	 (5.7)	 	
	 Endometrioid	 732	 195	 70.8	(61.5-81.5)	 694	 (12.4)	 38	 (13.5)	 	
	 Clear-cell	 328	 104	 90.9	(75.0-110.2)	 315	 (5.6)	 13	 (4.6)	 	
	 Adenocarcinoma	NOS	
899	 393	 143.0	(129.5-157.9)	 868	 (15.5)	 31	 (11.0)	 	
	 Others	 807	 216	 75.2	(65.8-85.9)	 778	 (13.9)	 29	 (10.3)	 0.002	
Prostateb	 all	 41118	 2927	 19.1	(18.4-19.8)	 	 	 	 	 	
	 Adenocarcinoma	 41017	 2882	 18.8	(18.1-19.5)	 31602	 (99.7)	 9415	 (99.8)	 	
	 Others	 101	 45	 191.5	(143.0-256.5)	 83	 (0.3)	 18	 (0.2)	 0.27	
Nervous	
systemc	
all	 10881	 3489	 100.4	(97.1-103.8)	 	 	 	 	 	
Astrocytic	 3856	 2869	 436.7	(421.0-452.9)	 3721	 (35.4)	 135	 (37.3)	 	
Oligodendroglial	
tumours	and	
mixed	gliomas	
585	 198	 104.6	(91.0-120.2)	 570	 (5.4)	 15	 (4.1)	 	
Ependymal		 323	 33	 24.9	(17.7-35.1)	 316	 (3.0)	 7	 (1.9)	 	
Glomas	of	
uncertain	origin	 239	 160	 337.0	(288.6-393.5)	 231	 (2.2)	 8	 (2.2)	 	
Medulloblastoma	 111	 52	 157.8	(120.2-207.0)	 106	 (1.0)	 5	 (1.4)	 	
Meningioma	 3237	 6	 0.4	(0.2-1.0)	 3129	 (29.7)	 108	 (29.8)	 	
Neurioma	 1370	 2	 0.3	(0.08-1.3)	 1325	 (12.6)	 45	 (12.4)	 	
Others	 1160	 169	 38.9	(33.5-45.3)	 1121	 (10.7)	 39	 (10.8)	 0.86	
Leukemiac	 all	 6636	 1618	 72.5	(69.1-76.2)	 	 	 	 	 	
	 Lymphatic	 2688	 431	 43.3	(39.4-47.6)	 2541	 (39.9)	 147	 (54.0)	 *	
	 Myeloid	 2304	 974	 147.5	(138.6-157.1)	 2246	 (35.3)	 58	 (21.3)	 *	
	 Monocytic	 135	 84	 312.5	(252.3-387.0)	 134	 (2.1)	 1	 (0.4)	 	
	 Others	 1509	 129	 23.5	(19.8-27.9)	 1443	 (22.7)	 66	 (24.3)	 <0.001	
 
a Chi-square test for difference in proportions between familial cancer patients and sporadic cancer patients 
b Sex-specific cancers 
c Excluded childhood cancers (diagnosis at age 0-14 years) 
* Histological type where difference occurred between familial cancer patients and sporadic cancer patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5		
Table 5. Histology-specific hazard ratios of cancer-specific death for familial cancer patients 
compared to sporadic cancer patients within 5 years of cancer diagnosis. 
 
Cancer	sites	 histology	
n.deaths	
HR	&	(95%	C.I.)	a	sporadic	 familial	
Stomach	 Adenocarcinoma	 1590	 115	 0.80	(0.66-0.96)	
	 Signet-ring	cell	carcinoma	 319	 23	 1.48	(0.93-2.36)	
	 Others	 137	 4	 0.52	(0.19-1.46)	
Breastb	 Tubular	 37	 4	 0.61	(0.22-1.73)	
	 Ductal	 2266	 343	 0.86	(0.76-0.96)	
	 Lobular	 328	 61	 0.99	(0.75-1.30)	
	 Others	 790	 122	 0.92	(0.76-1.12)	
Ovarianb	 Serous	 1095	 72	 1.06	(0.83-1.34)	
	 Mucinous	 147	 11	 2.09	(1.09-3.98)	
	 Endometrioid	 186	 9	 0.99	(0.50-1.97)	
	 Clear-cell	 100	 4	 1.05	(0.37-3.02)	
	 Adenocarcinoma	NOS	 381	 12	 0.80	(0.44-1.45)	
	 Others	 205	 11	 1.36	(0.73-2.52)	
Prostateb	 Adenocarcinoma	 2304	 578	 0.83	(0.76-0.91)	
	 Others	 37	 8	 1.13	(0.49-2.60)	
Nervous	systemc	 Astrocytic	 2764	 105	 1.09	(0.90-1.33)	
	 Oligodendroglial	tumours	and	mixed	gliomas	 193	 5	 0.75	(0.30-1.86)	
	 Ependymal		 32	 1	 2.09	(0.24-18.28)	
	 Glomas	of	uncertain	origin	 153	 7	 2.78	(1.16-6.65)	
	 Medulloblastoma	 49	 3	 1.09	(0.28-4.30)	
	 Meningioma	 6	 0	 -	
	 Neurioma	 2	 0	 -	
	 Others	 159	 10	 2.35	(1.12-4.93)	
Leukemiac	 Lymphatic	 409	 22	 0.94	(0.61-1.45)	
	 Myeloid	 951	 23	 0.92	(0.61-1.39)	
	 Monocytic	 84	 0	 -	
	 Others	 122	 7	 1.31	(0.60-2.86)	
 
a Hazard ratio (HR) with 95% confidence interval (C.I.) is from Cox regression model adjusting for sex, age at diagnosis, year of diagnosis, 
socioeconomic status and region of cancer diagnosis. 
b Sex-specific cancers 
c Excluded childhood cancers (diagnosis at age 0-14 years) 
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Table	6.	Observed counts of familial cancer patients and sporadic cancer patients stratified by tumor size/extent (T), lymph nodal involvement (N) and metastatic (M) status or 
FIGO categories between 2004 and 2009. Odds ratio (OR) and associated 95% Confidence Intervals (C.I.) for familial cancer patients vs. sporadic cancer patients are adjusted 
for sex, age at diagnosis, year of diagnosis, socioeconomic status and region of cancer diagnosis. 
 
Cancer	sites	by	TNM	 T1	 T2-T4	 P	a		 N-	 N+	 P	a	 M-	 M+	 P	a	
Stomach	 Sporadic	/	Familial	 98/8	 940/61	 0.56	 372/26	 648/47	 0.98	 633/41	 427/28	 1	
	 OR	&	95%	C.I.	 	 0.77(0.36-1.68)	 	 	 0.92	(0.55-1.54)	 	 	 1.05	(0.63-1.73)	 	
Breast 	 Sporadic	/	Famiial	 8613/1495	 5169/831	 0.10	 11418/1922	 3763/661	 0.40	 11922/2000	 316/53	 1	
	 OR	&	95%	C.I.	 	 0.94(0.85-1.03)	 	 	 1.04	(0.95-1.15)	 	 	 1.02	(0.76-1.37)	 	
Prostate	 Sporadic	/	Familial	 11220/3418	 9373/2633	 0.006	 2398/706	 426/115	 0.48	 4519/1294	 1098/280	 0.13	
	 OR	&	95%	C.I.	 	 0.95	(0.90-1.01)	b	 	 	 0.90	(0.72-1.13)	 	 	 0.89	(0.77-1.03)	 	
Cancer	site	by	FIGO	 I	 II-IV	 	 	 	 	 	 	 	
Ovarian	 Sporadic/	Familial	 565/13	 1268/74	 0.002	 	 	 	 	 	 	
	 OR	&	95%	C.I.	 	 2.70	(1.46-4.97)	c	 	 	 	 	 	 	 	
a Chi-square test for difference in proportions between familial cancer patients and sporadic cancer patients 
b OR=0.89 (95% CI = 0.81 to 0.97) for  T3 vs T1 
c OR=2.79 (95% CI = 1.21 to 6.40) for FIGO Stage II, OR=2.52 (95% CI=1.33 to 4.79), for FIGO Stage III, OR= 3.22 (95% CI = 1.52 to 6.79) for FIGO Stage IV comparing to the lowest FIGO Stage I 
	
 
 
 
 
 
 
 
 
 
 
 
 	
Supplementary Table 1. Observed counts of familial breast cancer patients and sporadic cancer patients stratified by tumor size/extent (T), lymph nodal involvement (N) 
and metastatic (M) status between 2004 and 2009. Odds ratio (OR) and associated 95% confidence intervals (C.I.) for familial cancer patients vs. sporadic cancer patients are 
adjusted for sex, age at diagnosis, year of diagnosis, socioeconomic status and region of cancer diagnosis. 
 
Cancer sites by TNM T1 T2-T4 P a N- N+ P a M- M+ P a 
Breast Sporadic / Famiial 8613/ 1495 5169 / 831 0.10 11418 / 1922 3763 / 661 0.40 11922 / 2000 316 / 53 1 
 OR & 95% C.I.  0.94 (0.85-1.03)   1.04  (0.95-1.15)   1.02 (0.76-1.37)  
Ductal Sporadic / Familial 6468/ 1140 3639 / 555 0.01 8271 / 1397 2837 / 468 0.68 8783 / 1450 177 / 30 0.90 
 OR & 95% C.I.  0.88 (0.78-0.98)   0.97 (0.86-1.09)   1.04 (0.70-1.54)  
Lobular Sporadic / Famiial 987 / 163 815 / 168 0.06 1448 / 259 489 / 104 0.17 1501 / 295 51 / 11 0.78 
 OR & 95% C.I.  1.26 (0.99-1.60)   1.33 (1.02-1.73)   1.21 (0.61-2.38)  
a Chi-square test for difference in proportions between familial cancer patients and sporadic cancer patients 																								
Supplementary Table 2. Overall and stratified (by histology) hazard ratios of cancer-specific death within 5 years of diagnosis and using all available follow-up 1993-2010. 
 
Cancer 
Sites Histology 
5-year follow-up All available follow-up 
n.deaths / n.patients 
HR & (95% C.I.) b 
n.deaths / n.patients 
HR & (95% C.I.) b sporadic familial sporadic familial 
Breast All a 3433 / 41173 535 / 7187 0.88 (0.80-0.96) 5324 / 41173 871 / 7187 0.91 (0.84-0.97) 
Tubular 37 / 2157 4 / 400 0.61 (0.22-1.73) 113 / 2157 16 / 400 0.75 (0.44-1.27) 
Ductal 2266 / 27723 343 / 4787 0.86 (0.76-0.96) 3444 / 27723 563 / 4787 0.91 (0.83-0.99) 
Lobular 328 / 5240 61 / 1000 0.99 (0.75-1.30) 633 / 5240 124 / 1000 1.05 (0.86-1.27) 
Others 790 / 5708 122 / 930 0.92 (0.76-1.12) 1122 / 5708 163 / 930 0.85 (0.72-1.001) 
Prostate All a 2341 / 31685 586 / 9433 0.83 (0.76-0.91) 3192 / 31685 821 / 9433 0.84  (0.78-0.91) 
Adenocarcinoma 2304 / 31602 578 / 9415 0.83 (0.76-0.91) 3152 / 31602 813 / 9415 0.84 (0.78-0.91) 
Others 37 / 83 8 /18 1.13 (0.49-2.60) 40 / 83 8 / 18 0.89 (0.39-2.03) 
a Note that hazard ratios may differ slightly from those on Table 2, which included patients from 1991. 
b Hazard ratio (HR) with 95% confidence interval (C.I.) from Cox regression model adjusting for age at diagnosis, year of diagnosis, socioeconomic status and region of cancer diagnosis. 		
